PET Imaging for Melanoma
Trial Summary
What is the purpose of this trial?
Current tests to detect cancer, including CAT scans and MRI scans, are limited. PET scans use special dyes that are injected into a vein and can better localize possible cancer. The investigators have developed a new particle that can carry a radioactive dye to a very specific area of the tumor. When using a PET scan the radioactive dye can be viewed in areas of possible disease. This particle has been studied in mice and was safe. The particles will not treat the cancer and any images or information found during this study will not be used for your treatment. The information collected may be used to guide the design of future studies to detect and/or treat tumors.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is 124I-cRGDY-PEG-dots safe for use in humans?
How does PET imaging for melanoma differ from other treatments?
PET imaging for melanoma is unique because it uses specialized radiotracers, like 18F-PEG3-FPN, to detect melanoma metastases with high precision, particularly in the liver and lungs, while minimizing liver uptake. This approach allows for better visualization of cancer spread compared to traditional imaging methods.24678
Research Team
Hilda Stambuk, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for adults with a confirmed diagnosis of melanoma or malignant brain tumor at MSKCC, who may have had prior treatments like surgery, chemo, or radiation. They must be able to use birth control and not have other recent cancers (except the one being studied), uncontrolled illnesses, severe heart disease, thyroid dysfunction, allergies to iodine contrast material, weigh over 400 lbs., or suffer from claustrophobia.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Microdosing Study
Participants receive a microdose of 124I-labeled cRGDY silica nanomolecular particle tracer for PET imaging to study biodistribution, pharmacokinetics, and metabolic stability
Follow-up
Participants are monitored for safety and radiation dosimetry after tracer administration
Treatment Details
Interventions
- 124I-cRGDY-PEG-dots
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor